Laurus Labs is currently trading at Rs. 379.00, up by 4.35 points or 1.16% from its previous closing of Rs. 374.65 on the BSE.
The scrip opened at Rs. 383.85 and has touched a high and low of Rs. 389.80 and Rs. 378.60 respectively. So far 1083 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 579.25 on 22-Dec-2017 and a 52 week low of Rs. 373.60 on 23-Oct-2018.
Last one week high and low of the scrip stood at Rs. 398.95 and Rs. 373.60 respectively. The current market cap of the company is Rs. 4033.95 crore.
The promoters holding in the company stood at 33.40%, while Institutions and Non-Institutions held 47.70% and 18.89% respectively.
Laurus Labs has transferred the US Food and Drug Administration (USFDA) approved Abbreviated New Drug Application (ANDA) of Tenofovir Disoproxil Fumarate (TDF) to CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to China and other markets.
The TDF is prescribed for the treatment of Hepatitis B virus (HBV). As part of the transaction, the company, in exchange of the transfer of ANDA, would receive certain upfront and milestone payments in different phases. Both parties are in discussions to allow Laurus to continue to manufacture and market TDF for the US market and to potentially supply API for the China market.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1864.40 |
Dr. Reddys Lab | 1390.20 |
Cipla | 1506.40 |
Lupin | 2227.40 |
Zydus Lifesciences | 973.60 |
View more.. |